EN2201(2C) - EN2201(2C): Carcinoids/PNET

METHOD OF PARTICIPATION

To complete this training, access to the internet is required. You must receive a minimum passing score of 80% on the post-test (max. 3 attempts) to receive your CME credit. Each module will have a required pre-test, educational component, and post-test.  If after three (3) attempts you are unsuccessful, you will be ineligible to receive CME credit and MOC for the module. However, content will always be available to you. It is important to know that once you have started the Post-Test (Examination), if you exit the Post-Test without responding to all questions, it will be counted as a failed attempt.

DATE

Original Release: September 1, 2021

Termination Date: November 30, 2022

ACCREDITATION STATEMENT

The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Washington School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MAINTENANCE OF CERTIFICATION (MOC) CREDITS:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

The University of Washington School of Medicine gratefully acknowledges receipt of educational grant funds in support of this CME activity from: AbbVie

SPEAKER & COURSE PLANNER DISCLOSURES

• Kit Wong, MD: Advisory Board: HalioDx, Genentech, Exelixis; Grant/Research Support: Pfizer, Tanabe, Astellas, Genentech, Adaptimmune, Replimmune
• Andrew Coveler, MD (Course Co-Chair/Planner/Reviewer/Speaker): no relevant financial relationships to disclose
• Ryan Cassaday, MD (Course Co-Chair/Planner/Reviewer/Speaker): Honoraria, Consulting/Speaking/Teaching, Advisory Committees/Review Panels and/or Grant/Research Support: Amgen, Kite/Gilead, Merck, Pepromene Bio, Pfizer, Vanda Pharmaceuticals
• David Zhen, MD (Course Reviewer/Speaker): Advisory Committees and/or Review Panels: QED Therapeutics

All relevant financial relationships have been mitigated.

PDF of Presentation